# Obesity and low lean mass are associated with dysregulated IGFBP-3, inflammatory biomarkers, and physical impairment in older adult women with frailty

**Authors:** Alan L. Fernandes, Rosa M. R. Pereira, Valeria F. Caparbo, Camila S. Figueredo, Caroline F. Gomes, Eduardo F. B. Neto, Diogo S. Domiciano

PMC · DOI: 10.3389/fragi.2026.1765052 · Frontiers in Aging · 2026-02-18

## TL;DR

In older women with frailty, obesity combined with low lean mass is linked to worse metabolic and inflammatory markers, suggesting a need for targeted interventions.

## Contribution

The study identifies specific biomarker profiles associated with obesity and low lean mass in frail older women.

## Key findings

- Obesity plus low lean mass is associated with lower IGFBP-3 and higher GDF-15 and resistin levels.
- Higher insulin levels and slower chair-stand performance are observed in obese individuals.
- GDF-15 correlates with slower chair-stand performance in these women.

## Abstract

Prior studies indicate sex-specific obesity-frailty interactions, with postmenopausal estrogen decline increasing sarcopenic obesity risk and inflammation in women. This study evaluated circulating cytokines (IL-6, TNF-α), adipokines (adiponectin, resistin), myokines (GDF-15, BDNF, myostatin), health-related biomarkers (IGF-1, IGFBP-3), and physical performance (five-times chair stand, grip strength) in pre-frail and frail older adult women classified as having low appendicular lean mass (LALM), obesity, or obesity plus LALM.

In this cross-sectional study, community-dwelling women aged ≥65 years from São Paulo, Brazil were screened (July 2022–September 2023); among 280 eligible, 88 met Fried frailty criteria. Body composition was assessed by DXA and participants were categorized as LALM (<20th percentile of residuals, −1.45), obesity (body mass index, BMI ≥30 kg/m2), or both. Generalized Estimating Equations (GEE) with Bonferroni post hoc adjustments, χ2, or Fisher’s exact tests were adopted. Unadjusted (P1) and age-adjusted (P2) P-values were reported.

Among 88 frail women (72.7% pre-frail and 27.3% frail), obesity plus LALM showed lower IGFBP-3 and higher GDF-15 vs. LALM (P2 = 0.041 and P2 = 0.032); obesity had higher resistin vs. LALM (P2 = 0.012), replicated in sensitivity analysis frail-only (P2 = 0.002), elevated insulin (P2 = 0.002) and a trend slower chair stand (P2 = 0.055). GDF-15 was related with chair stand time (Pearson r = 0.285, P = 0.006; and multiple regression β = 0.309, P = 0.013).

Among pre-frail and frail older adult women, obesity—with or without low lean mass—was associated with adverse metabolic/inflammatory profiles (higher resistin, GDF-15, insulin; lower IGFBP-3) in full and frail-only analyses, alongside a trend toward slower chair-stand performance. These cross-sectional findings highlight obesity-frailty interactions, warranting prospective validation.

## Linked entities

- **Proteins:** IGFBP3 (insulin like growth factor binding protein 3), IL6 (interleukin 6), TNF (tumor necrosis factor), LOC114022543 (uncharacterized LOC114022543), GDF15 (growth differentiation factor 15), BDNF (brain derived neurotrophic factor), LOC5521725 (growth/differentiation factor 8), IGF1 (insulin like growth factor 1)

## Full-text entities

- **Genes:** ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, MSTN (myostatin) [NCBI Gene 2660] {aka GDF8, MSLHP}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, IGFBP3 (insulin like growth factor binding protein 3) [NCBI Gene 3486] {aka BP-53, IBP-3, IBP3, IGFBP-3}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** Frailty (MESH:D000073496), skeletal muscle (MESH:D005207), metabolic disorders (MESH:D008659), muscle and fat abnormalities (MESH:D004620), COPD (MESH:D029424), non-communicable diseases (MESH:D000073296), overweight (MESH:D050177), falls (MESH:C537863), Obesity (MESH:D009765), chronic kidney disease (MESH:D051436), functional decline (MESH:D060825), weakness (MESH:D018908), diabetes (MESH:D003920), DD (MESH:C536170), dyslipidemia (MESH:D050171), impaired physical function (MESH:D059445), fractures (MESH:D050723), mitochondrial dysfunction (MESH:D028361), muscle catabolism (MESH:D019042), muscle wasting (MESH:D009133), Inflammation (MESH:D007249), liver disease (MESH:D008107), sarcopenia (MESH:D055948), diseases (MESH:D004194), neurodegeneration (MESH:D019636), cognitive impairment (MESH:D003072), chronic (MESH:D002908), pain-related (MESH:D000072716), declines in muscle function (MESH:D009135), dementia (MESH:D003704), low muscle (MESH:D009800), ALM (MESH:D013851), thyroid disorders (MESH:D013959), adiposity (MESH:D018205), weight loss (MESH:D015431), insulin resistance (MESH:D007333), age- (MESH:D019588), osteoporosis (MESH:D010024), hypertension (MESH:D006973), dual (MESH:D009105)
- **Chemicals:** cholesterol (MESH:D002784), triglycerides (MESH:D014280), bisphosphonates (MESH:D004164), alcohol (MESH:D000438), romosozumab (MESH:C557282), teriparatide (MESH:D019379), denosumab (MESH:D000069448)
- **Species:** Homo sapiens (human, species) [taxon 9606], Cosavirus F (no rank) [taxon 2003652]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957219/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12957219/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957219/full.md

---
Source: https://tomesphere.com/paper/PMC12957219